Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix GoSAN FRANCISCO, Jan. 05, 2024 (GLOBE...
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need...
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
RJVA-001 is the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate to be nominated by the Company and is designed...
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on...
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need...
Newport Beach, CA, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation , (“the Company” or “Bitech”) a global technology...
Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PTNEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics,...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to...
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s...
RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24Results of...
ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684...
A New Era for HoneyStick in Canada, TPB Canada’s Stewardship Includes Icons Such as Zig-Zag, Clipper, Choice Leaf, HMP, Rebound...
The Company will provide an update on its leading asset BNC210 and their partnership strategyADELAIDE, Australia and CAMBRIDGE, Mass., Jan....
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today...
VALNEVA Declaration of shares and voting rights December 31, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain...
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics...